Vericel Co. (NASDAQ:VCEL) Position Decreased by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P reduced its holdings in Vericel Co. (NASDAQ:VCEL) by 2.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,040,070 shares of the biotechnology company’s stock after selling 23,930 shares during the quarter. Loomis Sayles & Co. L P owned 2.11% of Vericel worth $43,943,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in VCEL. Vanguard Group Inc. increased its holdings in shares of Vericel by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,413,442 shares of the biotechnology company’s stock valued at $177,567,000 after buying an additional 39,349 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its position in shares of Vericel by 7.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 58,377 shares of the biotechnology company’s stock worth $3,036,000 after purchasing an additional 4,227 shares during the period. Advisors Asset Management Inc. lifted its holdings in shares of Vericel by 25.7% during the first quarter. Advisors Asset Management Inc. now owns 16,508 shares of the biotechnology company’s stock valued at $859,000 after purchasing an additional 3,374 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Vericel by 178.7% during the first quarter. Lazard Asset Management LLC now owns 2,584 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 1,657 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Vericel by 6.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 27,280 shares of the biotechnology company’s stock valued at $1,420,000 after purchasing an additional 1,721 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on VCEL. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Vericel in a report on Friday, November 8th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a report on Friday, November 8th. TD Cowen raised their price objective on shares of Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Canaccord Genuity Group reissued a “buy” rating and set a $60.00 target price on shares of Vericel in a research note on Tuesday, November 19th. Finally, Canaccord Genuity Group began coverage on Vericel in a report on Friday, August 9th. They issued a “buy” rating and a $57.00 target price for the company. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $58.14.

Vericel Trading Down 0.8 %

Shares of NASDAQ:VCEL opened at $58.62 on Tuesday. The firm has a market cap of $2.89 billion, a price-to-earnings ratio of 977.00 and a beta of 1.66. Vericel Co. has a 1 year low of $32.31 and a 1 year high of $61.49. The business has a fifty day simple moving average of $46.41 and a 200 day simple moving average of $47.07.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. The company had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. On average, sell-side analysts forecast that Vericel Co. will post 0.13 EPS for the current year.

Insider Buying and Selling at Vericel

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the sale, the chief executive officer now owns 220,937 shares of the company’s stock, valued at $9,142,373.06. This represents a 7.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $60.00, for a total transaction of $150,000.00. Following the completion of the sale, the director now owns 26,595 shares of the company’s stock, valued at $1,595,700. The trade was a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 31,666 shares of company stock worth $1,350,764 over the last ninety days. 5.20% of the stock is currently owned by insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.